Article
TGF-β signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis.
Journal of autoimmunity - 1 Jun 2018
Peres Raphael S, Donate Paula B, Talbot Jhimmy, Cecilio Nerry T, Lobo Patricia R, Machado Caio C, Lima Kalil W A, Oliveira Rene D, Carregaro Vanessa, Nakaya Helder I, Cunha Thiago M, Alves-Filho José Carlos, Liew Foo Y, Louzada-Junior Paulo, Cunha Fernando Q
Abstract excerpt
Rheumatoid arthritis (RA) is an autoimmune arthropathy characterized by chronic articular inflammation. Methotrexate (MTX) remains the first-line therapy for RA and its anti-inflammatory effect is associated with the maintenance of high levels of extracellular adenosine (ADO). Nonetheless, up to 40% of RA patients are resistant to MTX treatment and this is linked to a reduction of CD39 expression, an ectoenzyme...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.